Inspired by last week's #AskDrDurie episode in which Dr. Brian G.M. Durie of the IMF explained the definition of remission when it comes to myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
#AskDrDurie: What does IMWG’s new diagnostic criteria mean for myeloma patients?
Next Post
#AskDrDurie: How does the IMF contribute to the myeloma community?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.